Almitas Capital LLC Acquires Shares of 1,050,520 Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Almitas Capital LLC bought a new stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 1,050,520 shares of the company's stock, valued at approximately $672,000. Almitas Capital LLC owned approximately 0.36% of Lyell Immunopharma at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. RPO LLC purchased a new position in Lyell Immunopharma during the fourth quarter worth $42,000. Wells Fargo & Company MN grew its position in shares of Lyell Immunopharma by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 94,320 shares of the company's stock valued at $60,000 after purchasing an additional 20,542 shares during the period. SG Americas Securities LLC grew its holdings in Lyell Immunopharma by 102.8% in the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock valued at $75,000 after buying an additional 59,182 shares during the period. Barclays PLC increased its position in Lyell Immunopharma by 7.4% during the fourth quarter. Barclays PLC now owns 258,380 shares of the company's stock worth $165,000 after purchasing an additional 17,765 shares during the last quarter. Finally, Boothbay Fund Management LLC boosted its holdings in shares of Lyell Immunopharma by 190.4% in the 4th quarter. Boothbay Fund Management LLC now owns 406,234 shares of the company's stock valued at $260,000 after purchasing an additional 266,354 shares during the last quarter. Hedge funds and other institutional investors own 66.05% of the company's stock.

Insider Activity

In related news, CFO Charles W. Newton purchased 200,000 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $0.56 per share, with a total value of $112,000.00. Following the purchase, the chief financial officer now owns 200,000 shares of the company's stock, valued at $112,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard Klausner purchased 158,000 shares of the business's stock in a transaction dated Friday, March 14th. The shares were purchased at an average price of $0.60 per share, for a total transaction of $94,800.00. Following the acquisition, the director now directly owns 843,365 shares of the company's stock, valued at $506,019. This trade represents a 23.05 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 768,640 shares of company stock worth $449,508. 25.10% of the stock is owned by company insiders.

Lyell Immunopharma Stock Down 3.3 %

LYEL stock traded down $0.01 during midday trading on Wednesday, reaching $0.40. The company had a trading volume of 157,608 shares, compared to its average volume of 1,034,824. Lyell Immunopharma, Inc. has a fifty-two week low of $0.39 and a fifty-two week high of $2.88. The stock has a 50 day moving average price of $0.52 and a 200 day moving average price of $0.70. The firm has a market capitalization of $118.73 million, a PE ratio of -0.51 and a beta of -0.25.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The firm had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. Research analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "neutral" rating and set a $1.00 price target on shares of Lyell Immunopharma in a research report on Wednesday, April 16th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.